Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Different Doses of Indacaterol in Patients With Persistent Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Indacaterol 150 mcg
Drug: Indacaterol 27.5 mcg
Drug: Indacaterol 37.5
Drug: Indacaterol 55 mcg
Drug: Indacaterol 75 mcg
Drug: Placebo

First Posted Date: 2013-10-10

Last Posted Date: 2015-05-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 91

Registration Number: NCT01959412

Locations: 🇺🇸
Novartis Investigative Site, El Paso, Texas, United States

Effect of Glycopyrronium on Morning Symptoms and Pulmonary Function in Patients With Moderate to Severe COPD

Phase 4

Completed

Conditions: COPD

Interventions: Drug: Glycopyrronium
Drug: Tiotropium
Drug: Placebo to glycopyrronium
Drug: Placebo to tiotropium

First Posted Date: 2013-10-10

Last Posted Date: 2016-04-15

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 124

Registration Number: NCT01959516

Locations: 🇬🇧
Novartis Investigative Site, Wishaw, United Kingdom

Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD

Phase 4

Completed

Conditions: Neovascular Age-related Macular Degeneration

Interventions: Drug: Ranibizumab
Drug: Aflibercept

First Posted Date: 2013-10-09

Last Posted Date: 2019-03-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 712

Registration Number: NCT01958918

Locations: 🇨🇭
Novartis Investigative Site, Genève, Switzerland

Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors

Phase 2

Completed

Conditions: Solid Tumours

Interventions: Drug: Pazopanib

First Posted Date: 2013-10-08

Last Posted Date: 2020-08-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 57

Registration Number: NCT01956669

Locations: 🇪🇸
Novartis Investigative Site, Madrid, Spain

A Rollover Study to Provide Continued Treatment With Eltrombopag

Phase 4

Completed

Conditions: Thrombocytopaenia

Interventions: Drug: Eltrombopag (ELT)

First Posted Date: 2013-10-08

Last Posted Date: 2022-12-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 22

Registration Number: NCT01957176

Locations: 🇹🇳
Novartis Investigative Site, Sousse, Tunisia

Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer

Phase 3

Completed

Conditions: Advanced, Metastatic Breast Cancer

Interventions: Drug: Ribociclib
Drug: Letrozole
Drug: Placebo

First Posted Date: 2013-10-08

Last Posted Date: 2025-03-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 668

Registration Number: NCT01958021

Locations: 🇺🇸
Cooper Cancer Center, Camden, New Jersey, United States
🇺🇸
Uni Of TX MD Anderson Cancer Cntr, Houston, Texas, United States
🇺🇸
Ironwood Cancer and Research Centers, Chandler, Arizona, United States

and more 68 locations

Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)

Phase 3

Completed

Conditions: Psoriasis

Interventions: Biological: Secukinumab

First Posted Date: 2013-09-27

Last Posted Date: 2019-03-15

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 12

Registration Number: NCT01952015

Locations: 🇯🇵
Novartis Investigative Site, Kofu-city, Yamanashi, Japan

Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)

Phase 4

Completed

Conditions: End Stage Renal Disease (ESRD)
Chronic Kidney Disease (CKD)
Hemodialysis
Renal Replacement Therapy
Renal Transplantation

Interventions: Biological: Induction therapy
Drug: Corticosteroids
Drug: EVR+rCNI
Drug: MPA+sCNI

First Posted Date: 2013-09-26

Last Posted Date: 2019-01-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 2037

Registration Number: NCT01950819

Locations: 🇹🇷
Novartis Investigative Site, Mecidiyekoy/Istanbul, Turkey

Effect of Hepatic Impairment on LDK378 Pharmacokinetics

Phase 1

Completed

Conditions: Normal Hepatic Function
Impaired Hepatic Function

Interventions: Drug: LDK378

First Posted Date: 2013-09-25

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 36

Registration Number: NCT01950481

Locations: 🇺🇸
DaVita Clinical Research-Denver, Lakewood, Colorado, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸
Avail. Clinical Research, LLC, DeLand, Florida, United States

and more 2 locations

16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients

Phase 4

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: ENA713

First Posted Date: 2013-09-24

Last Posted Date: 2017-02-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 222

Registration Number: NCT01948791

Locations: 🇨🇳
Novartis Investigative Site, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy